An open-label, Phase I dose escalation study of theliatinib monotherapy in wild-type EGFR NSCLC

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 21 Sep 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Xiliertinib (Primary)
Indications Non-small cell lung cancer
Focus Adverse reactions

Most Recent Events

27 Sep 2016 New trial record
02 Aug 2016 According to a Chi-Med media release, this study has completed eight once-daily dose cohorts. The maximum tolerated dose has not yet been reached and dose escalation is continuing. company expects to conclude Phase II dose from this trial by the end of 2016.

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight